A Broad Portfolio of Promising Development Candidates

Helperby has 7 core development programmes using its platform for generating optimally matched combinations.

The principal markets for its new combinations of antimicrobials for bacterial infections are for urinary tract infections, intravenous-abdominal infections, cystic fibrosis and lung infections, prevention of post-surgical staphylococcal infections and skin infections.

In addition we now have a program aimed at a cure for the new coronavirus.